The MD Magazine Atherosclerosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


EBBINGHAUS Trial Finds No Cognitive Issues Associated with Evolocumab
Excitement has been surrounding PCSK9 inhibitors due to high efficacy in lowering cholesterol. However, two reports in 2015 found that two of these drugs (evolocumab and alirocumab) were linked to cognitive issues. A phase 3 trial at ACC 2017 set out to find if that's actually the case.
A synthetic version of "good" cholesterol failed to clear blocked arteries.
Jay Edelberg, MD, PhD, discusses the alirocumab phase 3 trial results at ACC 2017. “The results demonstrated that genetics really teach us a lot,” he said, noting that the majority of high-risk patients were able to achieve their treatment goals with just the 75 mg dose.
In a large, long-term clinical trial evolocumab reduced heart risk.
Details on why Pfizer pulled its PCSK9 inhibitor seen in SPIRE studies.
Regeneron/Sanofi will continue marketing, manufacturing, and selling alirocumab.
In a dramatic decision on a long-running patent dispute over alirocumab vs. evolocumab, a federal court judge ruled that Amgen's patents were violated and that rivals Sanofi/Regeneron can no longer distribute their product.
It's the third and final part of analyzing the book, Blue Latitudes, Boldly Going Where Captain Cook Has Gone Before, and how it applies to modern day.
If statins are good and PCSK9 inhibitors are better, how good will a combination be? Researchers reported today in a study called GLAGOV.

Most Popular


$vacMongoViewPlus$ $vAR$